Biotech firm plans stock sale

Article

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes oncology products, including the pain management product Quadramet and diagnostic radiopharmaceutical Prostascint. The company has exclusive U.S. marketing rights to Combidex, an investigational MR agent designed to aid in the diagnosis of metastatic lymph nodes.

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Emerging Innovations in Molecular Imaging
Related Content
© 2023 MJH Life Sciences

All rights reserved.